Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States

Published:2022-06-06 Issue:1 Volume:25 Page:703-711
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Berling Malin¹,Chaudhary Mohammad A.²^ORCID,Yuan Yong²,Varol Nebibe³,Dale Peter⁴,Testa Eleonora¹^ORCID,Klint Johan¹^ORCID,Lee Adam³^ORCID,Lubinga Solomon J.²^ORCID,Penrod John R.²

Affiliation:

1. Parexel International, Stockholm, Sweden

2. Bristol Myers Squibb, Princeton, NJ, USA

3. Bristol Myers Squibb, Uxbridge, UK

4. Parexel International, London, UK

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2077549

Reference51 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. American Cancer Society. Lung cancer survival rates; 2021. [cited 2021 June 15] Available from: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html.

3. Long-term survivors of more than 5 years in advanced non-small cell lung cancer

4. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial

5. Noone A, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review (CSR) 1975-2015; 2018. [cited 2021 October 26] Available from: https://seer.cancer.gov/archive/csr/1975_2015/.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview;Critical Reviews in Oncology/Hematology;2024-01

2. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer;International Immunopharmacology;2023-01